Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TL-021
- Development stage
- Preclinical
- Lead developer
- TrueLab Biopharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
TL-021 is a half-life extended bispecific antibody (HLE BsAb) currently in the discovery phase of development by TrueLab Biopharmaceutical. It is designed to simultaneously target Tumor Necrosis Factor-like Ligand 1A (TL1A) and the α4β7 integrin, two validated pathways in the pathogenesis of inflammatory bowel disease (IBD). TL1A is a cytokine that promotes mucosal inflammation and tissue fibrosis, while α4β7 integrin is responsible for the selective trafficking of pro-inflammatory lymphocytes to the gastrointestinal tract. By inhibiting both targets, TL-021 aims to provide a synergistic therapeutic effect for patients with Ulcerative Colitis (UC) and Crohn's Disease (CD) who may not respond adequately to existing monotherapies.
- Other names
- TL-021TL021TL 021
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)TL1A (TNF-like cytokine 1A)
Beyond the preview
Go deeper on TL-021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TL-021.